NCT01193361 - Ph IIA Study (SOC +/- NS5B) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

June 30, 2011

Study Completion Date

November 30, 2012

Conditions

Hepatitis C Virus

Interventions

DRUG

BMS-791325

Tablets, Oral, 75 mg, twice daily, 4-48 weeks depending on response

DRUG

BMS-791325

Tablets, Oral, 150 mg, twice daily, 4-48 weeks depending on response

DRUG

Placebo

Tablets, Oral, 0 mg, twice daily, 4-48 weeks depending on response

DRUG

Peg-interferon alfa-2a

Syringe, Subcutaneous Injection, 180 µg, once weekly, 4-48 weeks depending on response

DRUG

Ribavirin

Tablets, Oral, 1000 or 1200 mg based on weight, twice daily, 4-48 weeks depending on response

Trial Locations (10)

Mercy Medical Center, Baltimore

Digestive Disease Associates, P.A., Baltimore

Metropolitan Research, Fairfax

Charlotte Gastroenterology & Hepatology, Pllc, Charlotte

Loyola University Medical Center, Maywood

Options Health Research, Llc, Tulsa

The North Texas Research Institute, Arlington

Alamo Medical Research, San Antonio

Advanced Clinical Research Institute, Anaheim

Claudia T. Martorell, Md, Llc, Springfield